Drug combination

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Retrieved on: 
Monday, August 28, 2023
Research, Technology, Medical Devices, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, ICIS, ICI, GlobalData, Survival, Clinical trial, Cancer, Skin cancer, Immunotherapy, Bone marrow, ASCO, Patient, Machine learning, Melanoma, Drug combination, Artificial intelligence, Growth, AI, Therapy, Pharmaceutical industry, Lantern

These capabilities are expected to address the multiple challenges facing the increased usage of ICIs in cancer therapy.

Key Points: 
  • These capabilities are expected to address the multiple challenges facing the increased usage of ICIs in cancer therapy.
  • The success of ICIs has resulted in multiple competing ICI molecules, often from the same class, in overlapping cancer indications.
  • Additionally, recent clinical trial failures reveal headwinds to the desired expansion of ICIs for a broader range of cancers and patient groups.
  • "We are expanding the functionality of our RADR® AI platform in ways that aim to solve the very meaningful and important challenges of future checkpoint inhibitor development.

Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients

Retrieved on: 
Tuesday, May 30, 2023
Data management, Telehealth, Reuters, Therapy, GlobalData, Private, Clinical trial, Pharmacokinetics, DCT, Element, ASCO, Global Health, AUS, Science, Patient, SAN, Drug combination, Biostatistics, FDA, Medical writing, Nursing, Management, Pharmaceutical industry, Avance

Avance Clinical's Chief Scientific Officer, Gabriel Kremmidiotis

Key Points: 
  • Avance Clinical's Chief Scientific Officer, Gabriel Kremmidiotis
    According to Avance Clinical's Chief Scientific Officer Gabriel Kremmidiotis who is part of the Avance Clinical team attending ASCO:
    "Recently, Phase I clinical trial designs in Oncology patients have become more elaborate and include elements of dose escalation, dose expansion and assessment of drug combinations.
  • This, in addition to the increasing number of new emerging therapeutics, has increased the demand for fast progress through the early phases of development and a greater demand for access to patients."
  • "Utilizing Australia's regulatory environment and high-quality oncology experts, Avance Clinical is able to facilitate a fast project launch and seamless transition across different parts of modular oncology protocol designs.
  • Avance Clinical is at the cutting edge of clinical trial technology and has recently been ranked as the world leader in decentralised clinical trials (DCT) technology adoption by GlobalData and Clinical Trial Arena in the CRO sector.

Using AI in Drug Development to Enhance Preclinical Translatability, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 10, 2023
Informatics, Clarivate, Drug development, Failure, Pharmacovigilance, Health care, ML, Overfitting, Doctor of Philosophy, Machine learning, Drug combination, Toxicity, AI, DVM, Safety, Medical device, Risk management

TORONTO, Aug. 10, 2023 /PRNewswire-PRWeb/ -- Drug developers are increasingly turning to computational / in silico tools and methods to enhance novel drug investigation, as well as reduce costs and improve translation throughout the development lifecycle, from lead optimization through validation.

Key Points: 
  • In this free webinar, learn how exactly AI and ML techniques are taking computational modeling and informatics to new domains of applicability in the drug development lifecycle.
  • Through illustrative examples of AI in drug development, attendees will gain a better understanding of how these techniques can be applied to enhance decision-making and increase the chances of clinical success.
  • Enter artificial intelligence (AI) and increasing enthusiasm about the application of AI in drug development.
  • Join this webinar to learn how exactly AI and ML techniques are taking computational modeling and informatics to new domains of applicability in the drug development lifecycle.

Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Retrieved on: 
Monday, July 31, 2023
Bevacizumab, Investigational New Drug, LV, Therapy, Clinical collaboration, ESMO, Oxaliplatin, Cancer, Pharmacokinetics, Lead, Oncology, Annals of Oncology, Police, Patient, Colorectal cancer, Drug combination, Medicine, Knowledge, Investigational device exemption, Ides, CDX, European Society for Medical Oncology, Safety, Pharmaceutical industry, Medical device, Vaccine

BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Detsamma Investments Pty.

Key Points: 
  • BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Detsamma Investments Pty.
  • Deflexifol™ is a novel anti-cancer drug reformulation designed to address the safety and efficacy limitations of standard-of-care 5FU chemotherapy.
  • It combines, in a single infusion, 5FU and LV, a drug that potentiates 5FU anti-tumor activity, to improve the therapeutic activity of 5FU.
  • Financial terms of the clinical collaboration, option and potential license are not disclosed.

Susan G. Komen® Announces 2023 Grants to Accelerate Research Discoveries and Improve Outcomes for Breast Cancer Patients

Retrieved on: 
Wednesday, June 28, 2023
TNBC, DNA, Indiana University, University, Grant, Doctor of Philosophy, Cancer research, Eric, Pietenpol Air Camper, Vanderbilt University Medical Center, Research, Oncology, Government, Harvard Medical School, Puberty, Biochemistry, Patient, Breast cancer, Risk, Drug combination, Biology, Inclusion, GC, Disease, Pharmaceutical industry, Dietary supplement, Birth control, Nursing, Medicine

DALLAS, June 28, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced the awarding of 49 new grants to researchers at 28 leading institutions in the U.S. The $19.3 million in new grants support Komen's mission to end breast cancer through funding two focus areas: advancing precision medicine and eliminating disparities in breast cancer outcomes, while continuing Komen's commitment to supporting the next generation of diverse leaders in breast cancer research.

Key Points: 
  • The $19.3 million in new grants support Komen's mission to end breast cancer through funding two focus areas: advancing precision medicine and eliminating disparities in breast cancer outcomes, while continuing Komen's commitment to supporting the next generation of diverse leaders in breast cancer research.
  • Of the $19.3 million awarded:
    More than 65% supports research focused on the most aggressive breast cancers, including recurrent and metastatic breast cancer.
  • Nearly 40% supports research focused on understanding the causes and finding solutions to eliminate, reduce and address breast cancer disparities.
  • Komen has now invested nearly $1.1 billion in breast cancer research, the largest collective investment of any breast cancer nonprofit and second only to the U.S. government.

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, Technology, Professional Services, Health, Oncology, Health Technology, Research, Data Analytics, Software, Artificial Intelligence, Science, MSD, CRISPR, Drug development, Genomics, Biogen, Intelligence, Bristol Myers Squibb, Genome, Biomarker, Princeton University, Harvard Medical School, Milind, Bayer, GPC Biotech, Genome Therapeutics Corporation, Novartis, Patient, Commercial Affairs Department, MMV, Machine learning, Drug combination, Corporation, Drug discovery, Sanofi, Faculty, Entrepreneurship, Merck, AI, Merck & Co., Bavarian Nordic, Massachusetts General Hospital, Therapy, Medical device, Pharmaceutical industry, Management, Turbine

This investment brings the company’s oversubscribed Series A round to €25.5 million and adds further U.S.-based investors to the company’s financing syndicate.

Key Points: 
  • This investment brings the company’s oversubscribed Series A round to €25.5 million and adds further U.S.-based investors to the company’s financing syndicate.
  • Alongside the funding, Turbine announced the appointments of four independent directors to its board.
  • They also have the capacity to perform assays that would be impractical to conduct at scale and with high throughput.
  • Dr. Wegner believes Turbine’s pairing of AI with advanced biotechnology gives it potential to powerfully impact the future of healthcare.

Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit

Retrieved on: 
Tuesday, June 13, 2023
Therapy, Biotechnology, CDTX, Adenosine, DFC, Standard of care, Patient, SAN, Drug combination, The DFC, Immunosuppression, Tumor microenvironment, Pharmaceutical industry

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.

Key Points: 
  • SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.
  • The Adenosine-Pathway Targeted Cancer Immunotherapy Summit is a three-day conference that brings together over 80 industry and academic thought leaders to discuss the most recent advances of the last year in this field.
  • The meeting will aim to improve the understanding of adenosine signaling in the tumor microenvironment and discuss drug combinations to improve patient responses and overcome obstacles related to resistance and immunosuppression.
  • Oral presentation details are as follows:

ADDF STATEMENT ON FDA ADVISORY COMMITTEE'S ENDORSEMENT OF LECANEMAB (LEQEMBI)

Retrieved on: 
Friday, June 9, 2023
Fillit, Alzheimer's disease, Ageing, Biomarker, Patient, Alzheimer's Drug Discovery Foundation, Drug combination, PDUFA, Biology, Diagnosis, Entrepreneurship, Pharmaceutical industry, Medical imaging, Lecanemab

NEW YORK, June 9, 2023 /PRNewswire/ -- Today, the FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that lecanemab (leqembi) showed clinical benefit in early Alzheimer's disease, paving the way for a traditional approval of the drug. This milestone comes just ahead of its July 6th PDUFA date and if approved, Leqembi will be the first-ever disease-modifying treatment for Alzheimer's to receive full approval.

Key Points: 
  • This milestone comes just ahead of its July 6th PDUFA date and if approved, Leqembi will be the first-ever disease-modifying treatment for Alzheimer's to receive full approval.
  • "We are encouraged by the FDA Advisory Committee's decision to endorse Leqembi, but we recognize that the mission to develop effective treatments for all patients with Alzheimer's disease is far from over," says Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF).
  • As more new therapies move from discovery to development, there is an increased need to develop and utilize complimentary biomarkers and diagnostic tools that can identify the populations that will most benefit from various treatments.
  • "Biomarkers offer the ability to match the right drugs to the right patients at the right time," says Dr. Fillit.

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

Retrieved on: 
Friday, June 9, 2023
San Francisco, Tretinoin, University, European Hematology Association, CALC, University of California, San Francisco, Cancer, Juvenile myelomonocytic leukemia, Patient, Drug combination, Cytarabine, EHA, Calcitriol, Poster, Hospital, FLU, Pharmaceutical industry, JMML

FOSTER CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) at the European Hematology Association (EHA) Hybrid Congress being held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • Of 130 drug combinations, 27 were shown to be more active in killing leukemic cells ex vivo than compounds represented in these combinations on their own.
  • These results highlight PPMP as a potential tool for identifying superior drug combinations for patients with high medical needs, including with JMML.
  • Abstract title: Tretinoin and calcitriol enhance treatment regimens for juvenile myelomonocytic leukemia in ex vivo drug sensitivity assays.
  • Additional meeting information can be found on the 2023 EHA Congress website, https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .

Cybin Inc. Provides Corporate Update

Retrieved on: 
Thursday, June 8, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Alternative Medicine, Health, General Health, Other Science, Science, Momentum, Psilocybin, DMT, Tryptamine, Inc., DSM-IV codes, MDD, Patent, Patient, Mindfulness, Basic body-awareness methodology, Drug combination, Generalized anxiety disorder, NYSE, Safety, NEO, Pharmaceutical industry

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, provides a corporate update outlining access to capital and upcoming clinical milestones.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, provides a corporate update outlining access to capital and upcoming clinical milestones.
  • The potential access to capital should provide Cybin with the cash runway needed to complete these value-driving clinical milestones and enable us to continue focusing on clinical execution with the ultimate goal of bringing improved therapeutic options to patients in need,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • EMBARK provides six clinical domains (Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, and Keeping Momentum).
  • EMBARK is built upon four care cornerstones: trauma-informed care, culturally competent care, ethically rigorous care, and collective care.